Market Cap : 9.88 B | Enterprise Value : 8.43 B | PE Ratio : 16.43 | PB Ratio : 2.29 |
---|
NAS:UTHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:UTHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
United Therapeutics's average Accounts Payable for the three months ended in Jun. 2022 was $0 Mil. United Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2022 was $30 Mil. Hence, United Therapeutics's Days Payable for the three months ended in Jun. 2022 was 0.00.
The historical rank and industry rank for United Therapeutics's Days Payable or its related term are showing as below:
During the past 13 years, United Therapeutics's highest Days Payable was 87.90. The lowest was 11.76. And the median was 28.71.
UTHR's Days Payable is ranked worse thanUnited Therapeutics's Days Payable stayed the same from Jun. 2021 (0.00) to Jun. 2022 (0.00). stayed the same
The historical data trend for United Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, United Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, United Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
United Therapeutics's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as
Days Payable (A: Dec. 2021 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2020 ) | + | Accounts Payable (A: Dec. 2021 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2021 ) | * | Days in Period |
= | ( (4.1 | + | 3.8) | / | 2 ) | / | 122.5 | * | 365 |
= | 3.95 | / | 122.5 | * | 365 | ||||
= | 11.77 |
United Therapeutics's Days Payable for the quarter that ended in Jun. 2022 is calculated as:
Days Payable (Q: Jun. 2022 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Mar. 2022 ) | + | Accounts Payable (Q: Jun. 2022 )) | / | count ) | / | Cost of Goods Sold (Q: Jun. 2022 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 29.7 | * | 365 / 4 |
= | 0 | / | 29.7 | * | 365 / 4 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of United Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Benkowitz Michael | officer: President and COO | C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910 |
Maxwell Linda | director | 1040 SPRING STREET SILVER SPRING NC 27709 |
Thompson Tommy G | director | 7711 CARONDELET ST. LOUIS MO 63105 |
Mesa Nilda | director | C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 |
Klein Katherine J | director | STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104 |
Giltner Richard | director | C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009 |
Olian Judy D. | director | 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067 |
Edgemond James | officer: CFO and Treasurer | 1040 SPRING STREET SILVER SPRING MD 20910 |
Zaccardelli David | officer: EVP & Chief Operating Officer | 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069 |
Eli Lilly & Co | 10 percent owner | LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285 |
Ferrari John Maxim | officer: CFO & Treasurer | 1110 SPRING STREET SILVER SPRING MD 20910 |
Patusky Christopher | director | |
Hicks Henry Beecher Iii | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Gray R Paul | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Dwek Raymond | director |
From GuruFocus
Other Sources
By Zacks 2021-12-03
By Zacks 2021-10-20
By Zacks 2021-08-05
By Zacks 2021-11-03
By Zacks 2022-02-24
By Zacks 2022-02-16
By Zacks 2022-02-25
By Zacks 2021-08-04
By Zacks 2021-06-04
By Zacks 2021-06-04
By Zacks 2021-11-04